SCHEMBL6979815

SCHEMBL6979815

CC(C)(C)[C@H](NS(=O)(=O)c1ccc2ccccc2c1)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.60
SLC1A2 P43004 1/20 0.60
SLC1A1 P43005 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.53
ADAM17 P78536 1/20 0.52
KAT6A Q92794 4/20 0.50
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
TSHR P16473 2/20 0.49
CYP2C19 P33261 2/20 0.49
MAPT P10636 1/20 0.49
PKM P14618 1/20 0.49
PLAU P00749 1/20 0.48
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.48
GAA P10253 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
F2 P00734 2/20 0.47
LARS1 Q9P2J5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1770561 0.86 ADAM17 (0.60) SLC1A3SLC1A2SLC1A1L3MBTL1ADAM17
SCHEMBL1770556 0.86 ADAM17 (0.60) SLC1A3SLC1A2SLC1A1L3MBTL1ADAM17
SCHEMBL6979084 0.82 SLC1A3 (0.73) SLC1A3SLC1A2SLC1A1ADAMTS4MMP13
SCHEMBL8529829 0.82 SLC1A3 (0.73) SLC1A3SLC1A2SLC1A1ADAMTS4MMP13
SCHEMBL7322447 0.81 ADAMTS4 (0.66) SLC1A3SLC1A2SLC1A1L3MBTL1KAT6A
SCHEMBL10830548 0.81 ADAMTS4 (0.66) SLC1A3SLC1A2SLC1A1L3MBTL1KAT6A
SCHEMBL7354064 0.81 MMP9 (0.69) ADAM17ADAMTS4MMP13
SCHEMBL12435189 0.79 MMP1 (0.48) SLC1A3SLC1A2SLC1A1ADAM17CYP1A2
SCHEMBL6985255 0.79 ADAM17 (0.49) SLC1A3SLC1A2SLC1A1ADAM17CYP3A4
SCHEMBL4313196 0.78 MEP1B (0.51) L3MBTL1KAT6AALDH1A1LMNAADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0927716-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-05-07 EP disclosed
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed